Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of hepatitis B surface antigen with multiple GSK adjuvant systems in healthy HBV-naive adults
2008-004455-29Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2008
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of hepatitis b vaccine (recombinant), AS01B, AS01E, FLU-Q-PAN H7N9 Formulation 1 + AS03A and Hepatitis B vaccine in hepatitis B (HBV) (6 arms), sponsored by GSK. Primary endpoint: Cellular immune response to components of the investigational vaccine. Started Nov 2008; status: completed.
02
Drugs
hepatitis b vaccine (recombinant)AS01BAS01EFLU-Q-PAN H7N9 Formulation 1 + AS03AHepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2008-004455-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004455-29.